Back
Sanofi reports 1,214,099,027 shares outstanding as of June 30, 2026

Sanofi reports 1,214,099,027 shares outstanding as of June 30, 2026

Sanofi said real voting rights totaled 1,333,528,431 and theoretical voting rights reached 1,349,556,948 in a disclosure filed under French market rules.

Fact Check
All three figures in the claim are confirmed exactly by two sources: the GlobeNewswire regulatory disclosure ('Sanofi: Information concerning the total number of voting rights and shares - June 2026') and Sanofi's own official investor relations page ('Share, Structure and Voting Rights | Sanofi'). Both report 1,214,099,027 issued shares, 1,333,528,431 real voting rights, and 1,349,556,948 theoretical voting rights as of June 30, 2026, filed under French market rules (AMF Regulation and French Commercial Code).
    Reference: 12
Summary

Sanofi disclosed its total number of shares and voting rights as of June 30, 2026, under article L. 233-8 II of the French Commercial Code and article 223-16 of the Autorité des Marchés Financiers’ general regulation. The company reported 1,214,099,027 issued shares. Real voting rights, excluding treasury shares, stood at 1,333,528,431, while the theoretical number of voting rights, including treasury shares, was 1,349,556,948. The filing cited Article 223-11 of the AMF general regulation for the theoretical voting rights calculation.

Terms & Concepts
  • Theoretical voting rights: A voting rights count that includes all shares carrying voting rights, including treasury shares under French market rules.
  • Treasury shares: A company’s own shares that it holds itself, which can affect voting-rights calculations.